On opening day of World Pork Expo, Aptimmune Biologics launched the world’s first commercially available mucosal PRRSV vaccine for swine administered via nasal spray.
Aptimmune’s autogenous mucosal PRRS vaccine utilizes the BARRICADE® proprietary vaccine technology, which offers producers and veterinarians a revolutionary approach to PRRSV management. The mucosal vaccine offers a new class of vaccine to combat a devastating and costly disease. BARRICADE® PRRSV combines three core components: First, a powerful and safe immune stimulating adjuvant based on mycobacterium whole cell lysate. Second, high-titer PRRSV antigen produced on ZMAC, the world’s only commercially available porcine based alveolar macrophage cell line. Lastly, Aptimmune’s proprietary nanoparticles deliver the vaccine payload to immune cells responsible for mucosal immunity, potentially offering enhanced cell-mediated immunity and antibody production.
“Aptimmune has benefited from ground-breaking research conducted at the University of Illinois, The Ohio State University, and several private companies,” said Aptimmune CEO Aaron Gilbertie during a press conference. “We are proud the launch of BARRICADE® validates our collaborative innovation model. We are exceptionally pleased with early customer feedback. In the coming months, we expect to launch additional vaccines formulated with BARRICADE®, including influenza.”
Gilbertie was joined at World Pork Expo by Dr. Jianqiang Zhang with the Iowa State University Veterinary Diagnostic Laboratory to talk about the new vaccine: Aptimmune press conference
Gilbertie explains more about the vaccine in this interview: Interview with Aptimmune CEO Aaron Gilbertie